Janus Kinase Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016; New Report Launched

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016 report provides comprehensive insights about pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase (JAK) Inhibitors.

This report provides information on the therapeutic development based on JAK Inhibitors mecahanism of action dealing with around 20+ active pipeline drugs. The report also covers the information for 20+ active companies involved in the therapeutic development of the products

Report Highlights:

• The report also includes the information regarding 2 marketed drugs and their current clinical status for various other indications that can touch market in near future.
• This report also has market analysis that covers various deals, agreements, collaborations, acquisitions between various pharma giants and mid-level companies for successful development and future growth of drugs based on this mechanism of action.
• This report provides information on the therapeutic development based on the Janus Kinase (JAK) Inhibitorsdealing with all the marketed and pipeline drugs.
• The report provides drug profile which includes product description, MOA, licensors & collaborators, development partner and chemical information.
• This report covers the comparative analysis of Janus Kinase (JAK) Inhibitors at various stages covering Marketed Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
• It also has highlighted the discontinued and dormant products.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Spanning over 103 pages and 15 Tables “Janus Kinase Inhibitor (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016” report covers Executive Summary Snapshot, Overview, Market Drivers, Pipeline Therapeutics, Marketed Drugs, Comparative Analysis, Therapeutic Assessment, Appendix. This trport Covered 11 Companies -  AbbVie, Astellas Pharma, CTI BioPharma, Cytopia Research, Gilead Science, BMS, YM BioSciences, Pfizer, Eli Lilly, Advinus, ATIL.

For more information Visit at: http://mrr.cm/JRD

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases